Safety and Allele-Specific Immunogenicity of a Malaria Vaccine in Malian Adults: Results of a Phase I Randomized Trial

Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial

Abstract Rationale Administration of

An Adaptive Phase I/II Randomized Placebo-controlled Trial to Determine Safety, Immunogenicity and Efficacy of Non-replicating ChAdOx1 SARS-CoV-2 Vaccine in South African Adults Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV

A Phase I/II, double-blinded, placebo-controlled, individually randomized trial to assess safety, i

Safety, immunogenicity, and efficacy results of a phase II trial of therapeutic vaccines for chronic HBV in the Gambia.

A phase 2a randomized study to evaluate the safety and immunogenicity of the 1790GAHB GMMA vaccine against Shigella sonnei administered intramuscularly to adults from a shigellosis-endemic country

Shigellosis is a mild-to-severe diarrheal infection caused by the genus Shigella and responsible for

MOESM1 of Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara

Additional file 1. Raw data set of the IgG and GIA responses for the phase 1 trial of PfAMA1 FVO [25

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.

BACKGROUND: The efficacy of bacille Calmette-Guérin (BCG) may be enhanced by heterologous vaccinati